lifespin GmbH and Premier Integrated Labs Bring AI-Powered Metabolomic Testing to Malaysia  

In a significant step towards advancing preventive and personalized medicine, lifespin GmbH has partnered with Premier Integrated Labs (PIL) to introduce AI-powered metabolomic testing in Malaysia. This collaboration represents a major leap in making cutting-edge diagnostic tools accessible to a broader population and reflects a growing global shift toward early disease detection and proactive healthcare. 

Why Malaysia? 

When asked about the decision to launch in Malaysia, Dr. Ali Tinazli, CEO of lifespin GmbH, emphasized the country’s strategic importance: “Malaysia is in the heart of Southeast Asia and within a six-hour flight, it can reach almost half of the world population. It is a country dedicated to attracting high tech and driving digital transformation along with a highly skilled workforce and strong demographics. Premier Integrated Labs (PIL) itself is a highly renowned organization and part of the Pantai Hospital within IHH, the world’s largest hospital healthcare provider with more than 100 hospitals across Asia. Hence, the activities in Malaysia are spearheading our wider global market building. All these aspects make it a geostrategically attractive location.”

A New Era for Metabolomic Testing 

Lifespin GmbH’s metabolomic testing leverages nuclear magnetic resonance (NMR) technology to analyze over 250 biomarkers from just 0.5 mL of blood. “Our test is blood-based – we are scanning about 0.5 mL of blood serum in the magnetic field of an NMR instrument. The obtained raw measurement data are processed with our proprietary software suite,” explained Dr. Tinazli. This multi-layered approach includes precise metabolite profiling, personalized reference ranges based on age and sex, and clinical interpretation of metabolomic profiles for conditions such as diabetes, cardiovascular health, liver and kidney function, and inflammation.  

Dr. Tinazli highlighted that this method stands apart from traditional diagnostics: “In traditional diagnostics – even in an annual check-up – the number of biomarkers is quite limited to a few to a maximum of about 20-30. This is driven mostly by historically established protocols of the incumbents in the 1970s–1990s. Hence, current standard-of-care is antiquated and cost-constrained because of inefficiencies. The consequence is that patients – especially with unspecific symptoms or asymptomatic conditions at the onset of a given disease – must be literally patient because of these constraints. In our case with the lifespin platform, you capture at one single scan about 250 biomarkers at high precision, which allows us to detect concentration patterns of metabolites and shifts in these patterns in a disease context. Hence, what happens in legacy systems tediously and over weeks or months at relatively high cost, is captured in our system at once at a fraction of the cost.” 

Transforming Healthcare with AI and Accessibility 

Artificial intelligence plays a central role in lifespin’s testing methodology. “We are capturing hundreds of biomarkers and their concentration ratios to each other. With our proprietary, highly curated, and fully digitized biobank of more than 250,000 human profiles, we have a strong foundation to build our algorithms. This allows us to use not only AI-based but our proprietary algorithms in general to recognize patterns and extract more relational data to finally apply this to a clinical context,” said Dr. Tinazli. 

“At the current stage, we are focusing on the drivers of the biggest concerns for health and health economics, which are non-communicable diseases, such as diabetes, cardiovascular, and liver diseases. We are developing add-ons to our General Health Assessment products, such as an insulin resistance score to assess the risk of developing diabetes years or decades before its onset,” he explained. 

Accessibility is a core aspect of the partnership with PIL, ensuring that patients in Malaysia can benefit from these advancements. “We have chosen PIL as part of Pantai Hospital in the global IHH network because, with their excellent coverage across Malaysia, they are accessible to large parts of the population. We are working on expansion across other countries in Southeast Asia as well as in the Middle East and Europe. In the mid-term, we are anticipating additional coverage of the US and select countries in Africa and South America. Our initial focus is Europe and Asia-Pacific because of accessibility and rate of adoption,” noted Dr. Tinazli. 

A Global Vision for the Future 

Lifespin GmbH is setting its sights on global expansion, with plans to scale its technology across major healthcare markets. “Having this partnership in place with IHH opens the possibility to expand the metabolomics-based General Health Assessment across the IHH network. There are very strong and dedicated players within IHH, such as Acıbadem Hospital in Türkiye, driving innovation in clinical metabolomics use cases. We are currently in the process of partner discussions in Europe and Asia-Pacific. Particularly, the Kingdom of Saudi Arabia (KSA) is very promising along with their national strong commitment to digital transformation and healthcare efficiency,” Dr. Tinazli shared. 

Looking ahead, lifespin GmbH is actively developing new products, including advanced health scores for conditions like insulin resistance, diabetes, cardiovascular diseases, and liver disease. “For the next 18 months, we are expecting to launch dedicated products for insulin resistance scoring, a diabetes panel for GLP-1 treatment patients (aka Ozempic users), advanced health scores for MASH, MASLD, CDK, and advanced health scores for cardiovascular diseases.” 

Summing up the company’s approach, Dr. Tinazli likened lifespin’s software engine to a SuperApp: “The General Health Assessment (GHA) is the super app, and the individual advanced health scores, which are disease-specific, are the microservices as add-ons.” 

As metabolomic testing continues to gain traction, lifespin GmbH remains committed to transparency and collaboration. “Sometimes I hear that all we do sounds too good to be true – especially laboratory clinicians are sometimes skeptical. Important is to understand that our platform uses data obtained by a physical analytical method (NMR – without the involvement of any biochemistry, enzymes, or labels) and processes these data with our software. In all instances, we are highly transparent and invite interested parties and business partners to our premises in Germany (near Munich) for a live demo. I do not want people to believe us; I want people to see and understand what we are doing. And of course, we do publish our findings in peer-reviewed journals,” he concluded. 

Lifespin GmbH’s partnership with Premier Integrated Labs marks a significant step forward in transforming healthcare, enabling more people to take proactive steps toward managing their health with advanced, data-driven insights. 

Join the MedTech Malta 2025 Experience  

From 12 to 14 November, Valletta will host MedTech Malta 2025, uniting global innovators, investors, and healthcare leaders. Whether you’re showcasing cutting-edge technology, exploring sponsorship opportunities, or contributing to critical industry discussions, this is your chance to make an impact.  

Engage with key stakeholders, elevate your presence in a fast-evolving sector, and be part of the conversations that matter. Don’t miss out—contact us at [email protected] to discover how you can get involved!